PCRX in the 13F filings
Pacira Biosciences Inc · CUSIP 695127100
- Quarter end
- 31 Dec 2023
- the date the book describes
- Filed
- 14 Feb 2024
- latest of these filings; the earliest 26 Jan 2024
- Managers listing it
- 5
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q3 2023 and Q4 2023; 4 listed it in both
- Shares listed
- 3,025,444
- combined, among listed positions
- Reported value
- $102m
- combined, at the quarter end
Among the 93 comparable managers: 3 buyers (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing PCRX in Q4 2023
5 of 5 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | 1,716,697 | $58m | 0.09% | Added | +102,700 | 13 Feb 2024 (the filing on sec.gov) |
| Baillie Gifford & Co | 1,063,266 | $36m | under 0.1% | Trimmed | -573,810 | 26 Jan 2024 (the filing on sec.gov) |
| Woodline Partners LP | 127,371 | $4.3m | under 0.1% | Added | +18,964 | 14 Feb 2024 (the filing on sec.gov) |
| First Eagle Investment Management LLC | 103,081 | $3.5m | under 0.1% | Trimmed | -104,551 | 8 Feb 2024 (the filing on sec.gov) |
| Brevan Howard Capital Management LP | 15,029 | $507k | under 0.1% | New | new | 14 Feb 2024 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Renaissance Technologies LLCexisting position · 1,716,697 shares now+102,700
- Woodline Partners LPexisting position · 127,371 shares now+18,964
- Brevan Howard Capital Management LPnew position · 15,029 shares now+15,029
Reductions
- Baillie Gifford & Coexisting position · 1,063,266 shares now-573,810
- First Eagle Investment Management LLCexisting position · 103,081 shares now-104,551
New positions and exits
New (1)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 3 | $232m | n.a. | n.a. |
| Q3 2013 | 3 | $325m | n.a. | n.a. |
| Q4 2013 | 2 | $349m | n.a. | n.a. |
| Q1 2014 | 3 | $399m | n.a. | n.a. |
| Q2 2014 | 3 | $525m | n.a. | n.a. |
| Q3 2014 | 8 | $891m | n.a. | n.a. |
| Q4 2014 | 6 | $510m | n.a. | n.a. |
| Q1 2015 | 3 | $396m | n.a. | n.a. |
| Q2 2015 | 4 | $357m | n.a. | n.a. |
| Q3 2015 | 7 | $180m | n.a. | n.a. |
| Q4 2015 | 5 | $659m | n.a. | n.a. |
| Q1 2016 | 5 | $344m | n.a. | n.a. |
| Q2 2016 | 6 | $194m | n.a. | n.a. |
| Q3 2016 | 4 | $62m | n.a. | n.a. |
| Q4 2016 | 2 | $41m | n.a. | n.a. |
| Q1 2017 | 3 | $33m | n.a. | n.a. |
| Q2 2017 | 5 | $71m | n.a. | n.a. |
| Q3 2017 | 2 | $53m | n.a. | n.a. |
| Q4 2017 | 5 | $64m | n.a. | n.a. |
| Q1 2018 | 6 | $37m | n.a. | n.a. |
| Q2 2018 | 3 | $23m | n.a. | n.a. |
| Q3 2018 | 7 | $133m | n.a. | n.a. |
| Q4 2018 | 9 | $143m | n.a. | n.a. |
| Q1 2019 | 8 | $152m | n.a. | n.a. |
| Q2 2019 | 9 | $234m | n.a. | n.a. |
| Q3 2019 | 10 | $130m | n.a. | n.a. |
| Q4 2019 | 7 | $228m | n.a. | n.a. |
| Q1 2020 | 9 | $190m | n.a. | n.a. |
| Q2 2020 | 8 | $307m | n.a. | n.a. |
| Q3 2020 | 5 | $344m | n.a. | n.a. |
| Q4 2020 | 5 | $335m | n.a. | n.a. |
| Q1 2021 | 4 | $313m | n.a. | n.a. |
| Q2 2021 | 6 | $303m | n.a. | n.a. |
| Q3 2021 | 6 | $251m | n.a. | n.a. |
| Q4 2021 | 6 | $269m | n.a. | n.a. |
| Q1 2022 | 6 | $332m | n.a. | n.a. |
| Q2 2022 | 5 | $239m | n.a. | n.a. |
| Q3 2022 | 5 | $206m | n.a. | n.a. |
| Q4 2022 | 5 | $144m | n.a. | n.a. |
| Q1 2023 | 6 | $174m | n.a. | n.a. |
| Q2 2023 | 8 | $174m | n.a. | n.a. |
| Q3 2023 | 5 | $111m | n.a. | n.a. |
| Q4 2023 | 5 | $102m | 3 | 2 |
| Q1 2024 | 3 | $108m | 2 | 2 |
| Q2 2024 | 4 | $113m | 3 | 1 |
| Q3 2024 | 4 | $41m | 3 | 2 |
| Q4 2024 | 4 | $68m | 3 | 2 |
| Q1 2025 | 7 | $178m | 6 | 1 |
| Q2 2025 | 5 | $117m | 3 | 2 |
| Q3 2025 | 4 | $109m | 0 | 4 |
| Q4 2025 | 5 | $57m | 17 | 11 |
| Q1 2026 | 3 | $45m | 6 | 20 |
| Q2 2026 | 3 | $49m | 14 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
PCRX and LLY →PCRX and JNJ →PCRX and VRTX →Choose a stock to compare with PCRX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own PCRX, latest filings →Back to the 13F Explorer →